🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14 results for “avelumab” Clear

  1. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Cancer Prevention Pharma (Ireland) Limited

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  3. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Cancer

    phase 3 small molecule active

    1 trial

  4. Zelenectide Pevedotin, BT8009, PEMBROLIZUMAB, AVELUMAB, CISPLATIN, CARBOPLATIN, GEMCITABINE

    BICYCLE THERAPEUTICS

    Locally advanced or metastatic urothelial cancer

    phase 3 small molecule active

    1 trial

  5. AVELUMAB, Erbitux 5 mg/mL solution for infusion

    Fondazione Telethon ETS

    recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  6. Avelumab

    Nektar Therapeutics UK Limited

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  7. Avelumab and Pepinemab

    VACCINEX, INC.

    Metastatic Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial

  8. BAY 73-4506, AVELUMAB

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Adult patients with advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  9. DOCETAXEL , AVELUMAB, FLUOROURACIL , OXALIPLATIN , CALCIUM FOLINATE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  10. OXALIPLATIN, AFLIBERCEPT, PANITUMUMAB, BEVACIZUMAB, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, IRINOTECAN, FLUOROURACIL, CETUXIMAB, AVELUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    COLORECTAL METASTATIC CANCER WITH MICROSATELLITE INSTABILITY

    phase 2 small molecule active

    1 trial

  11. VX15/2503 + avelumab

    VACCINEX, INC.

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  12. avelumab

    Nektar Therapeutics UK Limited

    Squamous Cell Carcinoma of the Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  13. avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin

    Jazz Pharmaceuticals Ireland Limited

    Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  14. GEMCITABINE HYDROCHLORIDE, CISPLATIN, AVELUMAB, CISPLATIN, CISPLATIN, CISPLATIN, CARBOPLATIN, CARBOPLATIN, GEMCITABINE HYDROCHLORIDE

    Fondazione Telethon ETS

    metastatic or locally advanced urothelial cancer

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources